down arrow

Scholar Rock Holding Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US80706P1030
USD
45.20
4.12 (10.03%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

42.8345.50

52 Week

22.7146.98
Valuation
Technical
Day's Volume

CASH

1.34 M

Shareholding (Mar 2025)

FII

28.62%

Held by 120 FIIs

DII

0

Held by 60 DIIs

Promoter

28.90%

How big is Scholar Rock Holding Corp.?

22-Jun-2025

As of Jun 18, Scholar Rock Holding Corp. has a market capitalization of $2.96 billion, with net sales of $0.00 million and a net profit of -$264.16 million over the last four quarters. The balance sheet shows shareholder's funds of $368.63 million and total assets of $474.92 million.

As of Jun 18, Scholar Rock Holding Corp. has a market capitalization of 2,957.55 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -264.16 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 368.63 million and total assets of 474.92 million.

Read More

What does Scholar Rock Holding Corp. do?

22-Jun-2025

Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing monoclonal antibodies for treating neuromuscular disorders, cancer, fibrosis, and anemia. It has a market cap of approximately $2.96 billion and reported a net profit loss of $75 million as of March 2025.

Overview:<BR>Scholar Rock Holding Corporation is a biopharmaceutical company engaged in the development of monoclonal antibodies for the treatment of diseases such as neuromuscular disorders, cancer, fibrosis, and anemia, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -75 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,957.55 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -84.58% <BR>Price to Book: 9.47<BR><BR>Contact Details:<BR>Address: 620 Memorial Dr Fl 2, CAMBRIDGE MA: 02139-4815 <BR>Tel: ['1 857 2593860', '1 917 601-1649'] <BR>Fax: 1 302 6555049 <BR>Website: https://scholarrock.com/

Read More

Who are in the management team of Scholar Rock Holding Corp.?

22-Jun-2025

As of March 2022, the management team of Scholar Rock Holding Corp. includes Mr. David Hallal as Independent Chairman, Mr. Tony Kingsley as President and CEO, and independent directors Ms. Kristina Burow and Dr. Michael Gilman.

As of March 2022, the management team of Scholar Rock Holding Corp. includes Mr. David Hallal, who serves as the Independent Chairman of the Board, and Mr. Tony Kingsley, who is the President, Chief Executive Officer, and a Director. Additionally, the board features independent directors Ms. Kristina Burow and Dr. Michael Gilman.

Read More

Is Scholar Rock Holding Corp. overvalued or undervalued?

25-Jun-2025

As of May 9, 2023, Scholar Rock Holding Corp. is considered overvalued with troubling financial ratios and a significant decline in its valuation grade, indicating severe inefficiencies and worse financial health compared to its peers, despite a strong one-year stock return.

As of 9 May 2023, Scholar Rock Holding Corp. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its troubling financial ratios, including a Price to Book Value of 10.41 and an EV to EBIT of -10.86, which suggest that the market is pricing in expectations that are not supported by its current earnings or asset performance. Furthermore, the Return on Capital Employed (ROCE) is alarmingly low at -8470.74%, reflecting severe inefficiencies in capital utilization.<BR><BR>In comparison to its peers, Scholar Rock's valuation metrics are less favorable; for instance, Avidity Biosciences has a P/E ratio of -9.5851 and an EV to EBITDA of -5.0262, while Janux Therapeutics shows a P/E of -17.5680 and an EV to EBITDA of -3.1688. These comparisons highlight that Scholar Rock's financial health is significantly worse than its competitors in the sector. Despite a strong one-year stock return of 293.85% compared to the S&P 500's 10.26%, the underlying financial metrics suggest that the stock is not justified at its current price of 33.28, reinforcing the conclusion that it is overvalued.

Read More

Is Scholar Rock Holding Corp. technically bullish or bearish?

29-Sep-2025

As of September 26, 2025, Scholar Rock Holding Corp. shows a neutral technical trend with mixed signals, having gained 347.98% over the past year but underperformed year-to-date with a return of -10.34% compared to the S&P 500's 12.96%.

As of 26 September 2025, the technical trend for Scholar Rock Holding Corp. has changed from mildly bearish to sideways. Currently, the overall stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The Bollinger Bands indicate bullish momentum on both weekly and monthly time frames. Daily moving averages are mildly bearish, and the KST shows a similar pattern with a weekly mild bearish and monthly bullish stance. The Dow Theory reflects no trend on the weekly chart and mildly bearish on the monthly chart. The OBV is mildly bullish weekly but mildly bearish monthly.<BR><BR>In terms of performance, the stock has shown strong returns over the past year, gaining 347.98%, significantly outperforming the S&P 500's 15.64% return. However, year-to-date, it has underperformed with a return of -10.34% compared to the S&P 500's 12.96%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,036 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

-135.32%

stock-summary
Price to Book

13.01

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-110 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.47%
0%
31.47%
6 Months
46.09%
0%
46.09%
1 Year
14.78%
0%
14.78%
2 Years
236.06%
0%
236.06%
3 Years
474.33%
0%
474.33%
4 Years
80.08%
0%
80.08%
5 Years
4.29%
0%
4.29%

Scholar Rock Holding Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Scholar Rock Holding Corp. technically bullish or bearish?

As of 26 September 2025, the technical trend for Scholar Rock Holding Corp. has changed from mildly bearish to sideways. Currently, the overall stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The Bollinger Bands indicate bullish momentum on both weekly and monthly time frames. Daily moving averages are mildly bearish, and the KST shows a similar pattern with a weekly mild bearish and monthly bullish stance. The Dow Theory reflects no trend on the weekly chart and mildly bearish on the monthly chart. The OBV is mildly bullish weekly but mildly bearish monthly. In terms of performance, the stock has shown strong returns over the past year, gaining 347.98%, significantly outperforming the S&P 500's 15.64% return. However, year-to-date, it has underperformed with a return of -10.34% compared to the S&P 500's 12.96%....

Read More

Is Scholar Rock Holding Corp. technically bullish or bearish?

As of 26 September 2025, the technical trend for Scholar Rock Holding Corp. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The Bollinger Bands indicate bullishness on both weekly and monthly time frames. Daily moving averages are mildly bearish, and the KST shows a similar pattern with a weekly mildly bearish and monthly bullish stance. The Dow Theory indicates no trend on the weekly and mildly bearish on the monthly. The On-Balance Volume is mildly bullish weekly but mildly bearish monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 25.65% and 14.71%, respectively, compared to the S&P 500's -0.31% and 2.75%. However, it has underperformed year-to-date and over the last year, with a return of -1...

Read More

Is Scholar Rock Holding Corp. technically bullish or bearish?

As of 3 September 2025, the technical trend for Scholar Rock Holding Corp. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a bearish moving average on the daily timeframe. The KST indicates a mildly bearish trend on the weekly, while the Bollinger Bands show a mixed signal with a mildly bearish stance on the weekly and mildly bullish on the monthly. The stock has underperformed significantly year-to-date with a return of -24.85% compared to the S&P 500's 12.22%, although it has shown strong performance over the past year with a return of 292.74% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-223.34%
EBIT to Interest (avg)
-137.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.41
EV to EBIT
-10.86
EV to EBITDA
-10.93
EV to Capital Employed
920.17
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8470.74%
ROE (Latest)
-84.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 58 Schemes (47.01%)

Foreign Institutions

Held by 120 Foreign Institutions (28.62%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -47.26% vs -12.33% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-111.70",
          "val2": "-76.70",
          "chgp": "-45.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.80",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-110.00",
          "val2": "-74.70",
          "chgp": "-47.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -48.55% vs -23.27% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-250.10",
          "val2": "-168.50",
          "chgp": "-48.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-246.30",
          "val2": "-165.80",
          "chgp": "-48.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-111.70
-76.70
-45.63%
Interest
1.20
1.80
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-110.00
-74.70
-47.26%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -47.26% vs -12.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-250.10
-168.50
-48.43%
Interest
6.80
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-246.30
-165.80
-48.55%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -48.55% vs -23.27% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Scholar Rock Holding Corp. stock-summary
stock-summary
Scholar Rock Holding Corp.
Pharmaceuticals & Biotechnology
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.
Company Coordinates stock-summary
Company Details
620 Memorial Dr Fl 2 , CAMBRIDGE MA : 02139-4815
stock-summary
Tel: 1 857 25938601 917 601-1649
stock-summary
https://scholarrock.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."